Douglas J Macneil

List of Publications by Year
in descending order

49 papers	5,394 citations	172207 29 h-index	197535 49 g-index
51 all docs	51 docs citations	51 times ranked	5656 citing authors

#	Article	IF	Citations
1	Variations in DNA elucidate molecular networks that cause disease. Nature, 2008, 452, 429-435.	13.7	840
2	Analysis of Streptomyces avermitilis genes required for avermectin biosynthesis utilizing a novel integration vector. Gene, 1992, 111, 61-68.	1.0	684
3	Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3240-3245.	3.3	529
4	Neither Agouti-Related Protein nor Neuropeptide Y Is Critically Required for the Regulation of Energy Homeostasis in Mice. Molecular and Cellular Biology, 2002, 22, 5027-5035.	1.1	383
5	Melanin-Concentrating Hormone Receptor Subtypes 1 and 2: Species-Specific Gene Expression. Genomics, 2002, 79, 785-792.	1.3	258
6	Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nature Genetics, 2009, 41, 415-423.	9.4	257
7	Cloning and Expression of a Novel Neuropeptide Y Receptor. Journal of Biological Chemistry, 1996, 271, 16435-16438.	1.6	249
8	Role of the Y1 Receptor in the Regulation of Neuropeptide Y-Mediated Feeding: Comparison of Wild-Type, Y1 Receptor-Deficient, and Y5 Receptor-Deficient Mice. Endocrinology, 2000, 141, 1011-1016.	1.4	218
9	Complex organization of the Streptomyces avermitilis genes encoding the avermectin polyketide synthase. Gene, 1992, 115, 119-125.	1.0	184
10	Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metabolism, 2006, 4, 275-282.	7.2	174
11	Liver and Adipose Expression Associated SNPs Are Enriched for Association to Type 2 Diabetes. PLoS Genetics, 2010, 6, e1000932.	1.5	161
12	Production of the antitumor drug epirubicin (4â€²-epidoxorubicin) and its precursor by a genetically engineered strain of Streptomyces peucetius. Nature Biotechnology, 1998, 16, 69-74.	9.4	147
13	L-152,804: Orally Active and Selective Neuropeptide Y Y5 Receptor Antagonist. Biochemical and Biophysical Research Communications, 2000, 272, 169-173.	1.0	135
14	Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 13866-13871.	3.3	96
15	Antiobesity Effect of a Melanin-Concentrating Hormone 1 Receptor Antagonist in Diet-Induced Obese Mice. Endocrinology, 2005, 146, 3080-3086.	1.4	73
16	A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7154-7158.	3.3	72
17	Transformation ofStreptomyces avermitilis by plasmid DNA. Journal of Industrial Microbiology, 1987, 2, 209-218.	0.9	66
18	The Role of Melanin-Concentrating Hormone and Its Receptors in Energy Homeostasis. Frontiers in Endocrinology, 2013, 4, 49.	1.5	65

#	Article	IF	Citations
19	Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Research, 2004, 999, 227-230.	1.1	61
20	Characterization of Neuropeptide Y (NPY) Y5 Receptor-Mediated Obesity in Mice: Chronic Intracerebroventricular Infusion ofd-Trp34NPY. Endocrinology, 2003, 144, 1793-1801.	1.4	57
21	Novel Sesquiterpenoids from the Fermentation ofXylariapersicariaAre Selective Ligands for the NPY Y5 Receptor. Journal of Organic Chemistry, 2002, 67, 5001-5004.	1.7	56
22	NPY-induced feeding involves the action of a Y1-like receptor in rodents. Regulatory Peptides, 1998, 75-76, 409-415.	1.9	55
23	Insights about the biosynthesis of the avermectin deoxysugar L-oleandrose through heterologous expression of Streptomyces avermitilis deoxysugar genes in Streptomyces lividans. Chemistry and Biology, 2001, 8, 681-700.	6.2	49
24	NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs. Current Topics in Medicinal Chemistry, 2007, 7, 1721-1733.	1.0	48
25	Synthesis and Biological Evaluation in Vitro of Selective, High Affinity Peptide Antagonists of Human Melanin-Concentrating Hormone Action at Human Melanin-Concentrating Hormone Receptor 1. Biochemistry, 2002, 41, 6383-6390.	1.2	47
26	Introduction of plasmid DNA intoStreptomyces lividansby electroporation. FEMS Microbiology Letters, 1987, 42, 239-244.	0.7	46
27	A Pair-Feeding Study Reveals That a Y5 Antagonist Causes Weight Loss in Diet-Induced Obese Mice by Modulating Food Intake and Energy Expenditure. Molecular Pharmacology, 2007, 71, 602-608.	1.0	40
28	2-Aminoquinoline melanin-concentrating hormone (MCH)1R antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5270-5274.	1.0	32
29	Short Segment of Human Melanin-Concentrating Hormone That Is Sufficient for Full Activation of Human Melanin-Concentrating Hormone Receptors 1 and 2. Biochemistry, 2001, 40, 9379-9386.	1.2	29
30	2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4833-4837.	1.0	27
31	Correlation of the Avermectin Polyketide Synthase Genes to the Avermectin Structure: Implications for Designing Novel Avermectins. Annals of the New York Academy of Sciences, 1994, 721, 123-132.	1.8	25
32	Synthesis and Biological Evaluation in Vitro of a Selective, High Potency Peptide Agonist of Human Melanin-concentrating Hormone Action at Human Melanin-concentrating Hormone Receptor 1. Journal of Biological Chemistry, 2002, 277, 13821-13826.	1.6	23
33	Effects of a Novel Y5 Antagonist in Obese Mice: Combination With Food Restriction or Sibutramine. Obesity, 2008, 16, 1510-1515.	1.5	23
34	Melanin-concentrating hormone 1-receptor antagonist suppresses body weight gain correlated with high receptor occupancy levels in diet-induced obesity mice. European Journal of Pharmacology, 2009, 624, 77-83.	1.7	19
35	Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1564-1568.	1.0	19
36	Increased Melanin Concentrating Hormone Receptor Type I in the Human Hypothalamic Infundibular Nucleus in Cachexia. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2412-2419.	1.8	15

#	Article	IF	Citations
37	4-Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1R) antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5275-5279.	1.0	14
38	Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice. Journal of Endocrinology, 2008, 198, 309-315.	1.2	13
39	Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2911-2915.	1.0	12
40	Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension. ACS Medicinal Chemistry Letters, 2017, 8, 128-132.	1.3	12
41	A flexible boiling procedure for isolating plasmid DNA from gram-positive microorganisms. Journal of Microbiological Methods, 1986, 5, 115-123.	0.7	11
42	Neuropeptide Y receptors as targets of obesity treatment. Expert Opinion on Therapeutic Patents, 2006, 16, 1701-1712.	2.4	11
43	Vectors for generating nested deletions and facilitating subcloning G + C-rich DNA between Escherichia coli and Streptomyces sp.. Gene, 1992, 119, 149-150.	1.0	10
44	Chronic administration of nalmefene leads to increased food intake and body weight gain in mice. European Journal of Pharmacology, 2004, 495, 63-66.	1.7	10
45	MCH receptor peptide agonists and antagonists. Peptides, 2009, 30, 2008-2013.	1.2	10
46	Deficiency in Cytosolic Malic Enzyme Does Not Increase Acetaminophenâ€Induced Hepatoâ€Toxicity. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 36-42.	1.2	9
47	Expression, refolding, and purification of recombinant human phosphodiesterase 3B: definition of the N-terminus of the catalytic core. Protein Expression and Purification, 2004, 35, 225-236.	0.6	8
48	The role of tryptophan 1072 in human PDE3B inhibitor binding. Biochemical and Biophysical Research Communications, 2003, 307, 1045-1050.	1.0	6
49	NPY and energy homeostasis: an opportunity for novel anti-obesity therapies. , 2006, , 143-156.		2